JP2022543555A5 - - Google Patents

Info

Publication number
JP2022543555A5
JP2022543555A5 JP2022505487A JP2022505487A JP2022543555A5 JP 2022543555 A5 JP2022543555 A5 JP 2022543555A5 JP 2022505487 A JP2022505487 A JP 2022505487A JP 2022505487 A JP2022505487 A JP 2022505487A JP 2022543555 A5 JP2022543555 A5 JP 2022543555A5
Authority
JP
Japan
Prior art keywords
mirna
composition according
cancer
pten
source
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022505487A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022543555A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/055965 external-priority patent/WO2021028081A1/en
Publication of JP2022543555A publication Critical patent/JP2022543555A/ja
Publication of JP2022543555A5 publication Critical patent/JP2022543555A5/ja
Pending legal-status Critical Current

Links

JP2022505487A 2019-08-12 2020-03-06 ｍｉＲＮＡ－１９３ａに関する新たな処置 Pending JP2022543555A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19191222.9 2019-08-12
EP19191222 2019-08-12
EP20160235 2020-02-28
EP20160235.6 2020-02-28
PCT/EP2020/055965 WO2021028081A1 (en) 2019-08-12 2020-03-06 New treatments involving mirna-193a

Publications (2)

Publication Number Publication Date
JP2022543555A JP2022543555A (ja) 2022-10-13
JP2022543555A5 true JP2022543555A5 (enExample) 2023-03-10

Family

ID=69701219

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022505487A Pending JP2022543555A (ja) 2019-08-12 2020-03-06 ｍｉＲＮＡ－１９３ａに関する新たな処置

Country Status (7)

Country Link
US (1) US20220275368A1 (enExample)
EP (1) EP4013869A1 (enExample)
JP (1) JP2022543555A (enExample)
CN (1) CN114729358A (enExample)
AU (1) AU2020327537A1 (enExample)
CA (1) CA3148713A1 (enExample)
WO (1) WO2021028081A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020245822A1 (en) * 2019-06-03 2020-12-10 Carmel Haifa University Economic Corporation Ltd. Human head and neck cancer treatment
AU2020327537A1 (en) * 2019-08-12 2022-03-03 Interna Technologies B.V. New treatments involving miRNA-193a
CN114672558B (zh) * 2021-12-29 2023-08-04 河北医科大学第三医院 肝癌药物仑伐替尼耐药机制的研究方法
WO2023162872A1 (ja) * 2022-02-22 2023-08-31 株式会社 レオロジー機能食品研究所 抗がん剤及び抗がん剤のスクリーニング方法
EP4529562A2 (en) * 2022-05-23 2025-04-02 Empirico Inc. Treatment of sos2 related diseases and disorders
CN116850289B (zh) * 2022-07-29 2025-10-28 东北大学 Plk4靶向药物在治疗对铂类药物耐药型肿瘤中的应用
CN117144008B (zh) * 2023-08-31 2024-03-08 武汉科技大学 三阴性乳腺癌生物标志物及其应用
WO2025111565A1 (en) * 2023-11-22 2025-05-30 Empirico Inc. Treatment of sos2 related diseases and disorders
WO2025155574A1 (en) * 2024-01-16 2025-07-24 University Of Houston System, Board Of Regents Modulation of akap12 signalosome
CN118671343B (zh) * 2024-06-25 2025-04-29 南昌大学第一附属医院 一种头颈鳞状细胞癌分子标记物及其应用
WO2026013165A1 (en) * 2024-07-10 2026-01-15 Université Libre de Bruxelles Combination of ship2 inhibitor and plk1 inhibitor for use in the treatment of cancer
CN118987030B (zh) * 2024-07-16 2025-05-30 广东医科大学附属医院 干预嗜碱性粒细胞exosc3在制备预防或治疗狼疮性肾炎药物中的应用
CN119015428B (zh) * 2024-10-29 2024-12-20 中国人民解放军总医院第三医学中心 一种敲低tmem91诱导肾癌细胞死亡和肿瘤免疫治疗肾癌的应用
CN120989248B (zh) * 2025-10-23 2025-12-23 山东第二医科大学 一种检测lncRNA标志物表达量的试剂在制备口腔鳞状细胞癌诊断产品或预后判断产品中的应用
CN122168762B (zh) * 2026-05-13 2026-07-31 山东第一医科大学附属肿瘤医院(山东省肿瘤防治研究院、山东省肿瘤医院) Ubald2作为标志物在肝细胞癌诊断产品中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1089600A (en) 1998-05-15 2000-01-17 Tcs Engineering Services, Inc. Enhanced aircraft cockpit configuration
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
EA015363B1 (ru) 2003-07-18 2011-06-30 Эмджен Инк. Агенты, специфически связывающие фактор роста гепатоцитов, и их применение
FR2872704B1 (fr) 2004-07-12 2007-11-02 Laurent Schwartz Pluritherapie contre le cancer
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
MX2008015138A (es) 2006-06-02 2009-01-28 Aveo Pharmaceuticals Inc Proteinas de union al factor de crecimiento de hepatocitos (fch).
US7649083B2 (en) 2006-06-02 2010-01-19 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding antibody
JP4933548B2 (ja) 2006-07-20 2012-05-16 パナソニック株式会社 超音波探触子
WO2009091982A1 (en) 2008-01-18 2009-07-23 Alnylam Pharmaceuticals, Inc. Mir-122 agonist
TW200948380A (en) 2008-04-11 2009-12-01 Galaxy Biotech Llc Combination of HGF inhibitor and PTEN agonist to treat cancer
EP2591106A1 (en) * 2010-07-06 2013-05-15 InteRNA Technologies B.V. Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
US8691750B2 (en) * 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
EP3369818B1 (en) 2011-12-22 2021-06-09 InteRNA Technologies B.V. Mirna for treating head and neck cancer
WO2015022545A2 (en) * 2013-08-14 2015-02-19 Reneuron Limited Stem cell microparticles and mirna
WO2017180587A2 (en) * 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
WO2019106605A1 (en) 2017-12-01 2019-06-06 Board Of Regents, The University Of Texas System Combination treatment for cancer
WO2019155094A1 (en) * 2018-02-12 2019-08-15 Interna Technologies B.V. Anticancer microrna and lipid formulations thereof
AU2020327537A1 (en) * 2019-08-12 2022-03-03 Interna Technologies B.V. New treatments involving miRNA-193a
US20230136088A1 (en) * 2020-02-28 2023-05-04 Interna Technologies B.V. miRNA-193a for Promoting Immunogenic Cell Death

Similar Documents

Publication Publication Date Title
JP2022508155A5 (enExample)
US20250195641A1 (en) Immunotherapeutic constructs and methods of their use
JP7090034B2 (ja) 化学療法、標的療法、光線力学療法、免疫療法及びそれらの任意の組み合わせのためのナノ粒子
CN111150853B (zh) 一种肿瘤联合治疗药物载体的制备及应用
JP2015520143A5 (enExample)
JP2010526917A5 (enExample)
JP2017513931A (ja) 超分子コンビナトリアル治療薬
JP2013543844A (ja) 高分子コポリマーを含む治療用ナノ粒子
JP2004517045A5 (enExample)
JP2015512943A5 (enExample)
JP2013538213A5 (enExample)
JP2010528122A5 (enExample)
JP2014523413A5 (enExample)
US10829427B2 (en) Naphthoquinones, pro-drugs, and methods of use thereof
JP6842779B2 (ja) 二本鎖核酸分子、およびその用途
JP2023546316A5 (enExample)
US9415011B1 (en) Method for treatment of liver cancer and inhibition of metastasis with CXC-chemokine-receptor 4-targeted nanoparticle
JP4814245B2 (ja) 低酸素選択性抗腫瘍剤としてのスルホニルヒドラジンのリン酸含有プロドラッグ
JP2024521209A5 (enExample)
JP7345167B2 (ja) ポリ（カルバメート）－核酸医薬コンジュゲート、ポリ（カルバメート）核酸医薬コンジュゲートの凝集粒子、及び凝集粒子の製造方法
JP2011500841A5 (enExample)
JP2024520856A (ja) Ｆｇｆｒ４選択的阻害剤の塩及びその製造方法と用途
WO2022242438A1 (zh) 一种texaphyrin-叶酸螯合物及其制备方法与应用
CN114569733B (zh) 一种吗替麦考酚酯的亚油酸偶联前药在抗纤维化或/和抗肿瘤药物中的应用
WO2017077307A1 (en) Therapy and pharmaceutical composition